Home drugs Tecentriq (Atezolizumab)

Tecentriq (Atezolizumab)

This page contains brief information about atezolizumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)        Tecentriq
FDA Approved              Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Atezolizumab is approved to treat:

  • Non-small cell lung cancer that has metastasized (spread to other parts of the body). It is used in patients whose disease has gotten worse during or after treatment with platinum chemotherapy. For patients whose cancer has a mutation in the epidermal growth factor receptor (EGFR) gene or anaplastic lymphoma kinase (ALK) gene, atezolizumab is used if their disease has gotten worse after treatment with FDA-approved therapy for these mutations.
  • Urothelial carcinoma (a type of bladder cancer) that is locally advanced or has metastasized. It is used in:
    • Patients whose cancer has the PD-L1 protein and cannot be treated with cisplatin.
    • Patients whose cancer cannot be treated with platinum chemotherapy or has gotten worse during or after treatment with platinum chemotherapy.

Atezolizumab is also being studied in the treatment of other types of cancer.

More About Atezolizumab

Definition from the TCH Drug Dictionary – Detailed scientific definition and other names for this drug.

MedlinePlus Information on Atezolizumab – A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.